Merck & Co., Inc. (MRK.NYSE) AI FORECASTS & ADVISOR ANALYSIS

In this scenario, Merck executes a flawless 'soft landing' for the Keytruda franchise. The subcutaneous formulation (SC) receives broad FDA approval with favorable patent exclusivity extending into the 2030s, effectively converting 50%+ of the intravenous volume and mitigating the 2028 patent cliff. Concurrently, Winrevair (sotatercept) significantly outperforms consensus, becoming a $6B+ peak revenue megablockbuster by 2028. The ADC collaboration with Daiichi Sankyo yields two best-in-class assets that rapidly gain market share in lung and breast cancer. Macroeconomically, a rotation back into high-quality defensive value stocks with strong dividends favors Merck. The market re-rates MRK from a 10-11x P/E to a 15-16x multiple as revenue visibility clears past 2028, driving the stock toward new all-time highs above $160.

In the bear case, the 2028 Loss of Exclusivity (LOE) for Keytruda proves catastrophic. Competitors flood the market with biosimilars faster than anticipated, and the subcutaneous defensive strategy faces regulatory setbacks or limited payer reimbursement, leading to a steep revenue drop. Winrevair uptake is hampered by safety monitoring requirements or slow payer access, capping peak sales below $2B. The Inflation Reduction Act (IRA) aggressively targets Keytruda and Januvia, compressing margins earlier than modeled. Pipeline assets, including the Daiichi ADCs, experience clinical delays or fail to differentiate in a crowded oncology market. Investors view Merck as a 'value trap' with shrinking earnings, compressing the valuation multiple to single digits (8-9x P/E) and pinning the stock in the $80-$90 range.